Conditionally Active Biologics (CABs) are gaining fresh momentum—and this time, it’s not hype leading the way.
After decades of complex science and cautious optimism,
the field has entered a new phase: one powered by smarter
protein engineering, hard-earned clinical insights, and
technologies that unlock activity only where it counts. With
early clinical results, multiple platform advances, and a wave of strategic investment, CABs have now demonstrated proof of concept—and market belief.
That evolution—and what it means for oncology, autoimmunity, and beyond—was the focus of a standout panel at the 2025 BIO International Convention. Titled “Beyond Bispecifics and ADCs: Conditionally Active Biologics,” the session brought together R&D leaders, biotech innovators, and investors to explore how CABs are emerging as powerful tools of precision, persistence, and broader clinical impact.
Moderator Michael Rice, SVP of Advanced Therapeutics at
Lumanity, opened the conversation with a challenge: Why now? Why are CABs re-emerging as one of the most promising frontiers in biologics? The answer, echoed across the panel, pointed to a shared conclusion: the field is reaching a tipping point—scientifically, strategically, and commercially.
Download Full Recap
"*" indicates required fields
